These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35759972)

  • 1. Generation of an induced pluripotent stem cells line, CSSi014-A 9407, carrying the variant c.479C>T in the human iduronate 2-sulfatase (hIDS) gene.
    Casamassa A; Zanetti A; Ferrari D; Lombardi I; Galluzzi G; D'Avanzo F; Cipressa G; Bertozzi A; Torrente I; Vescovi AL; Tomanin R; Rosati J
    Stem Cell Res; 2022 Aug; 63():102846. PubMed ID: 35759972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.
    Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R
    J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of an induced pluripotent stem cell line (TRNDi008-A) from a Hunter syndrome patient carrying a hemizygous 208insC mutation in the IDS gene.
    Hong J; Xu M; Li R; Cheng YS; Kouznetsova J; Beers J; Liu C; Zou J; Zheng W
    Stem Cell Res; 2019 May; 37():101451. PubMed ID: 31071499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.
    Hong J; Cheng YS; Yang S; Swaroop M; Xu M; Beers J; Zou J; Huang W; Marugan JJ; Cai X; Zheng W
    Exp Cell Res; 2022 Mar; 412(1):113007. PubMed ID: 34990619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
    Mashima R; Ohira M; Okuyama T; Onodera M; Takada S
    Sci Rep; 2023 May; 13(1):7865. PubMed ID: 37188686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the two iduronate-2-sulfatase cDNAs.
    Daniele A; Di Natale P
    Biochem Mol Biol Int; 1995 Jun; 36(2):311-7. PubMed ID: 7663435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
    Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
    Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II.
    Hoshina H; Shimada Y; Higuchi T; Kobayashi H; Ida H; Ohashi T
    Mol Genet Metab; 2018 Feb; 123(2):118-122. PubMed ID: 29289480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase.
    Kosuga M; Mashima R; Hirakiyama A; Fuji N; Kumagai T; Seo JH; Nikaido M; Saito S; Ohno K; Sakuraba H; Okuyama T
    Mol Genet Metab; 2016 Jul; 118(3):190-197. PubMed ID: 27246110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational spectrum of the iduronate-2-sulfatase gene in Mexican patients with Hunter syndrome.
    Ramírez-Hernández MA; Figuera LE; Rizo-de la Torre LC; Mendoza-Ruvalcaba MTMSC; Arnaud-López L; García-Ortiz JE; Zúñiga-González GM; Puebla-Pérez AM; Gómez-Meda BC; Gallegos-Arreola MP
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5115-5127. PubMed ID: 35916809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
    Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
    BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment.
    D'Avanzo F; Rigon L; Zanetti A; Tomanin R
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA.
    Wilson PJ; Morris CP; Anson DS; Occhiodoro T; Bielicki J; Clements PR; Hopwood JJ
    Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8531-5. PubMed ID: 2122463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of a new mutation (1343-TT) in the iduronate-2-sulfatase gene from a Chinese patient with mucopolysaccharidosis type II].
    Guo YB; Du CS
    Zhonghua Er Ke Za Zhi; 2006 Feb; 44(2):110-3. PubMed ID: 16624026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
    Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of
    Smith MC; Belur LR; Karlen AD; Erlanson O; Podetz-Pedersen KM; McKenzie J; Detellis J; Gagnidze K; Parsons G; Robinson N; Labarre S; Shah S; Furcich J; Lund TC; Tsai HC; McIvor RS; Bonner M
    Hum Gene Ther; 2022 Dec; 33(23-24):1279-1292. PubMed ID: 36226412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II.
    Wang J; Bhalla A; Ullman JC; Fang M; Ravi R; Arguello A; Thomsen E; Tsogtbaatar B; Guo JL; Skuja LL; Dugas JC; Davis SS; Poda SB; Gunasekaran K; Costanzo S; Sweeney ZK; Henry AG; Harris JM; Henne KR; Astarita G
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.